Fulvio Mavilio, PhD

Fulvio Mavilio joined Orchard Therapeutics where he is serving as Chief Scientific Officer. Previously, Fulvio was Senior Vice President, Translational Science at Audentes Therapeutics; Chief Scientific Officer of Genethon and Adjunct Professor of Genetics at the Paris Descartes University in Paris, France; Director of Discovery of Molmed SpA; and co-founder and co-director of the HSR-Telethon Institute of Gene Therapy in Milan, Italy, where he developed the vector technology that formed the basis for the first-in-man use of genetically modified hematopoietic stem cells to treat a genetic disease (ADA deficiency), now Strimvelis®. He has served as a Board member in the American and European Societies of Gene and Cell Therapy, and on the Editorial Board of major international journals. Fulvio received his PhD in Medical Genetics at the University of Rome, Italy, and trained as postdoctoral fellow at the Wistar Institute in Philadelphia. An expert and a pioneer in gene therapy and stem cell research, he has published over 180 articles in major international journals.